Trial Profile
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cancer vaccine MUC-1 (Primary) ; Cancer vaccine MUC-1 (Primary) ; Molgramostim
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Vaxil BioTherapeutics
- 04 Sep 2012 The first two patients have been enrolled into the extension study (VAXIL-002) according to a Vaxil BioTherapeutics media release.
- 29 Aug 2012 Planned end date changed from 1 Oct 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 29 Aug 2012 Planned end date changed from 1 Oct 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.